What's in Boston Scientific Corporation's pipeline?

Boston Scientific Corporation has 15 drugs in our index: 3 marketed, 0 filed, 6 in Phase 3, 3 in Phase 2, 3 in Phase 1.

Which companies overlap with Boston Scientific Corporation's portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, Sanofi, Beijing Suncadia Pharmaceuticals Co., Ltd, ATGC Co., Ltd., Akeso.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/boston-scientific-corporation.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Boston Scientific Corporation — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Boston Scientific Corporation pipeline: 3 marketed, 0 filed, 6 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 6 Phase 3 3 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Anticoagulation with heparin	Anticoagulation with heparin	marketed	Anticoagulant	Antithrombin III (enhancer); Thrombin (Factor IIa); Factor Xa	Cardiovascular
P2Y12 antagonist	P2Y12 antagonist	marketed
Varithena®	Varithena®	marketed	Sclerosing agent	Vein endothelium (non-receptor mediated tissue damage)	Cardiovascular / Vascular
Anti-platelet therapy	Anti-platelet therapy	phase 3	Anti-platelet agent		Cardiovascular
Anti-coagulation therapy	Anti-coagulation therapy	phase 3
polidocanol injectable foam, 0.125%	polidocanol injectable foam, 0.125%	phase 3
polidocanol injectable foam, 0.5%	polidocanol injectable foam, 0.5%	phase 3	sclerosing agent		Dermatology
Thienopyridine	Thienopyridine	phase 3			Other
polidocanol injectable foam, 1.0%	polidocanol injectable foam, 1.0%	phase 3	sclerosing agent		Cardiovascular

Therapeutic area mix

Cardiovascular · 3
Cardiovascular / Vascular · 1
Dermatology · 1
Oncology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Sanofi · 2 shared drug classes
Beijing Suncadia Pharmaceuticals Co., Ltd · 2 shared drug classes
ATGC Co., Ltd. · 1 shared drug class
Akeso · 1 shared drug class
Amgen · 1 shared drug class
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
Anemia Working Group Romania · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Boston Scientific Corporation:

Cite this brief

Drug Landscape (2026). Boston Scientific Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/boston-scientific-corporation. Accessed 2026-05-18.